Seemed really odd to me too. It's so different from how things were handled a year ago. Leads me to believe that they're trying to focus on the the science and the trials(?) But really, seems like it should have been announced. It wasn't mentioned in recent presentations. Just seems kind of "seat of the pants". I don't have that much experience with biotech though so, maybe that's just how some operate.
In this instance, I do think this trial is a good thing. It's short and has a small number of participants at a single center. It should be quick, easy and cheap. If good efficacy, it could provide a nice little bump in both share price and confidence. If efficacy is so/so no big loss. My understanding is that there's a lot going on in the psoriasis trials area right now. I wonder if there might not have been a less crowded indication to go after?
My biggest concern is what to do with the warrants I currently hold. This, and the shorter duration fibrosis trial, are helping me make the decision to hold them in their current state a bit longer yet.
News 
Market Data 
Discover 
